Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Transplant Proc. 2009 Jun;41(5):1969-71. doi: 10.1016/j.transproceed.2009.02.100.

Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition.

Author information

  • 1Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA. Elliot.tapper@gmail.com


Portopulmonary hypertension (PoPH) is a common and feared complication of end-stage liver disease, and imposes increased risk of perioperative morbidity in the liver transplant patient. Herein, we present the first successful use of Imatinib in the perioperative management of a patient who was not responding to conventional treatments as well as our institution's experience with this devastating complication. Of patients evaluated for transplant, 4.1% were identified with PoPH, half of which were listed, and one quarter of which were transplanted. Patients with PoPH were twice as likely to be transplanted than all other candidates (48% vs 25%), though less likely to survive their first year (69% vs 86.4%).

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk